Seven-year data show lorlatinib keeps ALK+ lung cancer controlled, with durable brain protection, stable safety, and clues to early resistance.
Alice Shaw, MD, PhD
Advertisement
Articles by Alice Shaw, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
MAIC Shows OS Benefit With Mogamulizumab vs Vorinostat in Cutaneous T-Cell Lymphoma Subtypes
2
QOL, Efficacy, and Cost Considerations Help Drive TKI Treatment Selection in CML
3
From "Not Curable" to "May Be Curable": Joshua Richter, MD, on the New Reality of Multiple Myeloma
4
Revised Risk Stratifications Help Inform the Use of Adjuvant Cemiplimab and Neoadjuvant Strategies in Cutaneous Squamous Cell Carcinoma
5